GP software supplier DXS International (DXSP) has raised just over £1m at 8p a share. The shares equate to more than one-quarter of the enlarged share capital. The cash will provide working capital required to market the company’s new products. The latest framework agreement has included a modest price rise. NHS accreditation of the company’s new software should be completed in April.

Cancer treatments developer Incanthera is planning to join NEX Exchange this week. Manchester-based Incanthera is developing Sol, a topical product for the treatment of solar keratosis and prevention of skin cancer, which could be licenced to a partner within 18 months. There is a pipeline of cancer therapeutics which have come through the Institute of Cancer Therapeutics at Bradford University, which owns 12.3% of the company. AIM-quoted Immupharma (IMM) will hold an 11.9% stake and has 7.27 million warrants, where the exercise price is being rebased to the issue price. Cairn is the corporate adviser and Stanford Capital Partners is the broker. The expected admission date is 28 February.

NQ Minerals (NQMI) is paying A$2m for 100% of the Beaconsfield gold mine and processing plant in Tasmania. This was a major gold mine up until 2012 and it could go back into production. The gold price has risen by 50% since production stopped. The initial payment is A$100,000.

NAV fell from 64p a share to 59p a share at Western Selection (WESP) in the six months to December 2019. The lack of a dividend from AIM-quoted Bilby (BILB) meant that dividend income nearly halved, although it was the one core investment that increased in value. There will be no interim dividend. Share disposals mean that net cash was £2.45m at the end of 2019.

Gunsynd (GUN) has decided not to take up its option to acquire a further 22.33% stake in the Kolosori nickel prospect in the Solomon Islands. Previously £45,000 was paid for a 7.76% stake. Gunsynd has received £20,000 of the £260,000 it is due to be paid for its stake in Oyster Oil and Gas.

Primorus Investments (PRIM) says that investee company SOA Energy UK hopes to join AIM by the fourth quarter of 2020. Drilling is due to commence at the Ofek well in Israel during May and it could last 40 days with a further 40 days of testing. The results will be known before the flotation. Primorus owns 14,977 SOA shares.

Belvedere Leisure Resorts (BELV) is still waiting for cash to cover the full subscription promised just after flotation and it does not appear likely that the investor can come up with the cash. Other investors may come up with the funds in the next six weeks.

Investment company First Sentinel (FSEN) has raised £196,000 from an issue of Green Finance preference shares at 100p each. There is a fixed interest rate of 5.05% a year and then a variable rate of up to 10.15% depending on whether certain conditions are met. The preference are convertible into ordinary shares. The focus is on investments in the ethical, sustainable and renewable energy sectors.

Sativa Group (SATI) says subsidiary Goodbody Botanicals will have its products stocked in 100 of WH Smith Travel’s UK stores.

Angelfish Investments (ANGP) has appointed Novum Securities as its corporate adviser.

Editorial Disclaimer

SME news and commentary

NEX Exchange Limited (”NEX Exchange”) accepts no responsibility for the content of this article or for any reliance placed by you or any person on the information contained therein.

By providing access to this material NEX Exchange does not intend to solicit business or offer any securities to any person in any country, whether directly or indirectly.

Articles available on nexexchange.com may be produced by independent third parties and are for distribution only under such circumstances as may be permitted by such third parties and applicable law. They are published solely for informational purposes and should not be construed as a recommendation to sell, buy or hold any product, investment, security or any other financial instrument. Any opinion, view or idea contained in any article is the author’s own and does not reflect or represent the opinions, views or ideas of NEX Exchange, nor any of its affiliates, directors, officers, employees or agents. Publication of the article does not signify endorsement by NEX Exchange of any of the information contained therein. NEX Exchange is not involved in the preparation of any such articles and does not make any representation or warranty, express or implied, as to the accuracy, completeness, suitability or correctness of any of the information presented by individual authors in the articles. In no circumstances will NEX Exchange, or any of its affiliates, directors, officers, employees or agents, be liable for any indirect or direct loss, or consequential loss or damages including without limitation, loss of business or profits arising from the use of, any inability to use, or any inaccuracy in the Information or views contained in the articlesAny opinions expressed in the articles are subject to change without notice and are not to be relied upon as investment advice, which should be sought from your independent advisers. NEX Exchange is under no obligation to update or keep current the information contained in the articles.

Please refer to the NEX Terms of Use for further information